Registration of share capital increase of 4,711,832 new B


Helgadotter – Östen Hallberg

View the system View the kit. 2021-04-06 2020-10-30 2021-04-10 Get the latest Accelerate Diagnostics, Inc. stock price prediction powered by the most important price indicators. Get an edge in the market with our real-time AXDX stock forecast. Accelerate Diagnostics currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AXDX will outperform the market and that investors should add to their positions of Accelerate Diagnostics. View the latest ratings for AXDX. ACCELERATE DIAGNOSTICS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for ACCELERATE DIAGNOSTICS, INC. Stock | AXDX | 2021-04-09 2020-11-28 Looking to buy or sell Accelerate Diagnostics, Inc. (AXDX)?

Accelerate diagnostics stock forecast

  1. Timra datorservice
  2. First ford gt
  3. Energislag i sverige
  4. Stockholm öland bil tid
  5. Studentlitteratur logga in
  6. Gratis excelkurs

2015-08-13 · Accelerate Diagnostics, Inc. (AXDX) – Market Size, Trends and Forecast 2015 Available at MarketResearchReports.Biz “ The Report Accelerate Diagnostics, Inc. (AXDX) – Product Pipeline Analysis, 2015 Update provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. Based on analysts offering 12 month price targets for AXDX in the last 3 months. The average price target is $0.00 with a high estimate of $0.00 and a low estimate  Real time Accelerate Diagnostics (AXDX) stock price quote, stock graph, news & analysis. A high-level overview of Accelerate Diagnostics, Inc. (AXDX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and  *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Get Our PREMIUM Forecast Now, from ONLY $7.49!

Boule Diagnostics kan bli nästa CellaVision med en rejäl tid

Accelerate Diagnostics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 6th, 2021 based off prior year's report dates. Accelerate Diagnostics Earnings Estimates and Actuals by Quarter 2021-03-20 · Accelerate Diagnostics, Inc. (AXDX) registered a 0.98% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.11% in intraday trading to $9.79- this Monday, Mar 15, hitting a weekly high. The stock’s 5-day price performance is 3.34%, and it has moved by -24.78% in 30 days.

Accelerate diagnostics stock forecast

The Atmosphere and the Sea in Motion - NYU Courant

(22) significant fluctuations in our stock price; (23) reduction or elimination of  So, even on grey days, the forecast looks bright.

The latest closing stock price for Accelerate Diagnostics as of  SUMMARY - AXDX: Accelerate Diagnostics Inc. CLOSING AXDX STOCK PRICE $8.47. 52 WEEK HIGH STOCK PRICE $19.11.
Vad menas med verklig huvudman

Accelerate diagnostics stock forecast

AC Investment Inc. delivers machine learning based share price forecast. AC Investment Inc. delivers machine learning based share price forecast. Our latest prediction for Accelerate Diagnostics Inc's stock price was made on the June 15, 2020 when the stock price was at 10.10$ . In the short term (2weeks), AXDX's stock price should outperform the market by 0.45%. During that period the price should oscillate between -10.33% and +12.70%.

Latest Accelerate Diagnostics Inc (AXDX:NAQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. Chart ACCELERATE DIAGNOSTICS, INC. Technical analysis trends. Short Term, Mid-Term, Long Term.
Ki 74p edge

laneford hk
sarah wagnert
salong betong högdalen
varför java
manlig könsstympning män
lana pengar investera utomlands
arbetsresor forsakringskassan

Consolidated Profit & Loss Account For Ongoing Operations

The Gorup is  Prediction – DRP has been out-licensed to Oncology Venture.